Under one in 10 people who could benefit from weight-loss injections including Wegovy are able to get them, caution the World Health Organization as it releases its first recommendations on the medications.
Considering more than one billion people worldwide now classified as obese, it is advocating for broader and more equitable access to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"The latest guidance affirms that obesity is a chronic disease that can be managed with thorough and continuous support," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are major hurdles to universal access to the injections that can aid individuals in losing significant body mass, explains the body.
GLP-1 Therapy Supply Crisis
Despite the present best projected outlook, the manufacturing of such drugs could only cover approximately 100 million people – less than 10% of eligible patients, per the health organization.
The guideline urges governments and firms to expand access, by measures including patent sharing.
Exclusive production rights on the active ingredient – the main ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026.
How Obesity Drugs Operate
GLP-1 drugs replicate a biological compound to reduce digestion speed, reduce hunger and boost satiety so individuals eat less.
Patients commonly start to lose weight within a few weeks of beginning the regular doses.
Research indicates users may see weight return a year later of stopping the treatment, because their usual appetite come back.
To be above a healthy weight raises your risk for contracting health problems, like type 2 diabetes, heart disease, brain attack, and certain cancers.
Obesity concerns individuals in all nations and was linked to millions of deaths worldwide in 2024, per the WHO.
